Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) (MOSAIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03094832

Recruitment Status : Terminated (This study did not meet the efficacy objective)

First Posted : March 29, 2017

Last Update Posted : May 16, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Worldwide Clinical Trials

Information provided by (Responsible Party):

ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	April 11, 2022
Actual Study Completion Date :	April 11, 2022

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	March 6, 2023

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Forde K, Resta N, Ranieri C, Rea D, Kubassova O, Hinton M, Andrews KA, Semple R, Irvine AD, Dvorakova V. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome. Orphanet J Rare Dis. 2021 Feb 27;16(1):109. doi: 10.1186/s13023-021-01745-0.

To Top